Last reviewed · How we verify

Public Health Service of Amsterdam — Portfolio Competitive Intelligence Brief

Public Health Service of Amsterdam pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fosfomycin Oral Suspension Fosfomycin Oral Suspension marketed Cell wall synthesis inhibitor MurA (enolpyruvate transferase) Infectious Disease
Gentamicin Sulfate, Injectable Gentamicin Sulfate, Injectable phase 3 Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  2. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 shared drug class
  3. Hospital General Universitario Elche · 1 shared drug class
  4. Murdoch Childrens Research Institute · 1 shared drug class
  5. Mylan Inc. · 1 shared drug class
  6. Oslo University Hospital · 1 shared drug class
  7. Seattle Children's Hospital · 1 shared drug class
  8. Shanghai Pulmonary Hospital, Shanghai, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Public Health Service of Amsterdam:

Cite this brief

Drug Landscape (2026). Public Health Service of Amsterdam — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/public-health-service-of-amsterdam. Accessed 2026-05-18.

Related